Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of ...

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.

The S&P 500 gained 0.6% on Monday, March 31, boosted by an afternoon rally even as investors brace for the planned onset of ...

The temporary monovalent and bivalent booster ... Individuals 18 and older who received a Johnson & Johnson vaccine should ...

In the final days of President Joe Biden’s term, Moderna MRNA won the $590 million contract to use its mRNA vaccine technology for a bird-flu vaccine. Back To Top ...

Moderna stock has dropped more than 70% over the past year. The company’s coronavirus vaccine no longer is driving outsized growth -- and Moderna is still in the process of ushering in newer ...

Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration’s top vaccine official has been pushed out. Shares in some larger ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft ...

[5] It compared the accelerated schedule of the combined vaccine with the monovalent hepatitis A and B vaccines. Subjects received either the combined hepatitis A and B vaccine, administered on ...